[Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals.] jetcityimage Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) said a new analysis showed its oral weight-loss drug Foundayo (orforglipron) 17.2 mg delivered significantly greater weight loss and improved blood sugar control compared with oral semaglutide 25 mg in adults with type 2 diabetes. The findings [https://seekingalpha.com/pr/20666648-lillys-foundayo-orforglipron-17_2-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral], presented at the European Association for the Study of Diabetes meeting in Milan, are based on an indirect treatment comparison using data from the ACHIEVE-3 and PIONEER PLUS trials. At 52 weeks, patients taking Foundayo 17.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.